Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY

NCT03139487 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT03139487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03139487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
August 7, 2017
Completion date
September 30, 2021
Enrollment
176 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ampulla of vater cancer, biliary cancer (cholangiocarcinoma, gall bladder cancer), cancer-associated thrombosis, duodenal cancer, esophageal cancer, esophagogastric junction cancer, hepatocellular carcinoma, malignant gastrointestinal stromal tumor, pancreatic cancer, stomach cancer